EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Use of Enhanced Analytical Pipelines for the Characterization of Poly(A) and Poly(A)-LNP Formulation Critical Quality Attributes

Callum G Davidson iD, Eleni Kapsali, Savvas Ioannou, Bojan Kopilovic iD, Muattaz Hussain, Yvonne Perrie iD, Zahra Rattray iD

Molecular Pharmaceutics · 01.12.2025 · 22 (12) · 7383-7399

DOI: 10.1021/acs.molpharmaceut.5c00614 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 30.10.2025. Verfasst von Callum G Davidson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, U.K. Hauptthemen laut MEDLINE: Nanoparticles, Poly A, Lipids. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Engineering and Physical Sciences Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The number of nucleic acid therapeutics is set to grow within the pharmaceutical industry sector, deploying nanocarrier-based delivery systems as drug products. Poly(A) is a widely used model sequence used in lipid nanoparticle (LNP) formulations for which there are no reported critical quality attributes (CQAs) such as molecular weight, chain length, and impurity profile. In this study, we analyze Poly(A) from three different vendors to measure any existing differences in their CQAs. Poly(A) from these brands was encapsulated in SM102 LNPs using microfluidics to produce three branded Poly(A)-based LNPs. We utilized an orthogonal analytical pipeline approach for both Poly(A) drug substance and LNP drug product CQA evaluation, which included a combination of dynamic light scattering and flow field flow fractionation multiplexed with inline UV, dynamic, and multiangle light-scattering detectors. Similar purity (260/280) values of >3 were obtained across all three brands of Poly(A); however, distinct differences in molecular weight and chain length distributions were identified across Poly(A) brands, with this study representing the first to apply EAF4 methodology for in-depth characterization of model RNA drug substances. Brand A produced a smaller and broader molecular weight distribution, followed by Brand B, and then Brand C produced the largest molecular weight species and the most uniform molecular weight distribution. On encapsulation in LNPs, differences seen in Poly(A) CQAs did not translate to CQA differences in resultant LNPs. We show that a deeper understanding of drug substance CQAs and their subsequent impact on resultant overall drug product characteristics is needed on a case-by-case basis. We show correlations between analytical pipelines, with future work investigating the impact of RNA molecular weight in LNP formulations with different lipid compositions and using these correlations in AI or machine learning to further enhance our knowledge of the correlation between drug substance and resultant drug product CQAs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesPoly ALipidsDrug CompoundingChemistry, PharmaceuticalMolecular WeightLiposomes

Stichwörter der Autor:innen

EAF4LNPPoly(A)drug productdrug substance

Substanzen

Poly ALipidsLipid NanoparticlesLiposomes

Autor:innen und Institutionen

  • Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, U.K.
  • School of Molecular Biosciences, University of Glasgow, Glasgow G11 6EW, U.K.
  • School of Chemical, Materials and Biological Engineering, University of Sheffield, Sheffield S1 3JD, U.K.

ORCID-Profile: Callum G Davidson, Bojan Kopilovic, Yvonne Perrie, Zahra Rattray

Förderung

  • Engineering and Physical Sciences Research Council

Zitieren

APA

Davidson, C. G., Kapsali, E., Ioannou, S., Kopilovic, B., Hussain, M., Perrie, Y., & Rattray, Z. (2025). The Use of Enhanced Analytical Pipelines for the Characterization of Poly(A) and Poly(A)-LNP Formulation Critical Quality Attributes. Molecular Pharmaceutics, 22(12), 7383-7399. https://doi.org/10.1021/acs.molpharmaceut.5c00614

Vancouver

Davidson CG, Kapsali E, Ioannou S, Kopilovic B, Hussain M, Perrie Y, et al. The Use of Enhanced Analytical Pipelines for the Characterization of Poly(A) and Poly(A)-LNP Formulation Critical Quality Attributes. Molecular Pharmaceutics. 2025;22(12):7383-7399. doi:10.1021/acs.molpharmaceut.5c00614

BibTeX
@article{Davidson2025,
  author = {Davidson, Callum G and Kapsali, Eleni and Ioannou, Savvas and Kopilovic, Bojan and Hussain, Muattaz and Perrie, Yvonne and Rattray, Zahra},
  title = {The Use of Enhanced Analytical Pipelines for the Characterization of Poly(A) and Poly(A)-LNP Formulation Critical Quality Attributes},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  volume = {22},
  number = {12},
  pages = {7383--7399},
  doi = {10.1021/acs.molpharmaceut.5c00614}
}
Kostenlos starten →